Moderna has begun testing its COVID-19 vaccine on young children, the company announced Tuesday.

Axar.az reports that the study, called KidCOVE, is testing Moderna's vaccine candidate in children ages 6 months to less than 12 years old.

"It is humbling to know that 53 million doses have been administered to people in the U.S.," Stéphane Bancel, chief executive officer of Moderna, said in a statement. "We are encouraged by the primary analysis of the Phase 3 COVE study of mRNA-1273 in adults ages 18 and above and this pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population."